May 2025 FDA Recall Airsupra by Asttrazeneca Pharmaceuticals Lp
D-0444-2025 - Defective delivery system

This Class II drug recall was voluntarily initiated by Asttrazeneca Pharmaceuticals Lp on May 14, 2025 for the product Airsupra. The FDA reported the reason for recall as defective delivery system. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0444-2025

Reason for Recall
Defective delivery system
Initiated
05-14-2025
Reported
05-28-2025
Quantity
a) 807,837 canisters; b) 235,698 canisters

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
AsttraZeneca Pharmaceuticals LP
Airsupra (albuterol and budesonide) inhalation aerosol, 90 mcg/80 mcg per inhalation, packaged in a) 120-inhalation canister (NDC 0310-9080-12) b) 28-inhalation canister (NDC 0310-9080-28), Rx only, Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, By: AstraZeneca Dunkerque Production (AZDP), Dunkerque, France, Product of France, .

Batch or Lot Expiration Information

Lot# : a) 6270044C00, 6270040D00, 6270034E00, Exp Date 10/2026; 6270053C00, 6270045C00, 6270047C00, 6270056C00, 6270052C00, 6270063E00 Exp 11/30/2026; 6270064C00, 6270071D00, 6270075D00, 6270075F00 Exp Date 12/31/2026; 6270107C00, Exp Date 9/30/2027; b) Lot 6270019E00, Exp Date 7/31/2025; 6270021D00, Exp 8/31/2025; 6270095C00, Exp 2/28/2026

Affected Packages Involved in this Recall